MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
7.09
-0.38
-5.09%
After Hours: 7.09 0 0.00% 16:10 05/11 EDT
OPEN
7.40
PREV CLOSE
7.47
HIGH
7.45
LOW
7.05
VOLUME
59.88K
TURNOVER
--
52 WEEK HIGH
11.78
52 WEEK LOW
6.57
MARKET CAP
687.69M
P/E (TTM)
145.59
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GYRE last week (0504-0508)?
Weekly Report · 13h ago
Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)
TipRanks · 3d ago
Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sight Sciences (SGHT) and Gyre Therapeutics (GYRE)
TipRanks · 4d ago
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est
Benzinga · 4d ago
Gyre Therapeutics GAAP EPS of -$0.10, revenue of $22.5M
Seeking Alpha · 4d ago
Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
Benzinga · 4d ago
Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates
Reuters · 4d ago
More
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.